The SFA Group Launches Environmental Division: SFA enviro
SFA, a World-Renowned Group, launches its Environmental Division: SFA enviro. Specialized in the design and manufacture of Wastewater Treatment Equipment since 1958, the group is mainly known for having revolutionized the sanitary equipment market.
New division, SFA enviro, the result of the SFA Group's International Growth Strategy.
With more than 1,000 employees in 27 countries worldwide, the SFA Group has a portfolio of leading brands, including Europelec and Aquaturbo. The Group’s core business is closely linked to the Treatment of Municipal and Industrial Wastewater with a DNA focused on the Design and Manufacturing of Aeration Equipment.
Thanks to 100 years of cumulative and international experience, SFA enviro supplies most of the equipment for Wastewater Treatment plants - from pre-treatment to sludge management - including process and treatment tanks and specific ancillary equipment used to settle, decant, aerate, and thicken Wastewater.
Inventiveness is a priority for the SFA Group: Since the beginning, the Group has never stopped looking to the future and adapting to the ever-changing Market Place. Innovation, R&D, respect for the environment and customer service are at the heart of the Group's Core values. The SFA Group is committed to offering high performance with quality products, manufactured in Europe and the USA.
Companies part of SFA enviro Division: Europelec (France), Aquasystems International N.V. (Belgium) and Aquaturbo Systems Inc (USA).
R&D Department works in partnership with French and other higher education and research institutions.
Much of the Equipment has been in service Worldwide for more than 30 to 35 years, with references in many Industrial Sectors such as Dairy Industry, Pulp and Paper, Mining, Food Processing, Meat Rendering, Brewery Industries, Oil and Gas, Pharmaceutical Industry, Sugar production, Livestock and Fish farming etc...
Prestigious Customers: AQUAFIN, METITO, VEOLIA, SEVERN TRENT, SAUR, WATERLEAU, SUEZ, VINCI, NIJHUIS, BENTLEY, PANTAREIN, MAREL, NESTLÉ, ASIATEX, APP SINAR MAS, TOTAL ENERGIES, LACTALIS, SACROFINA, TEREOS, GRUMA, AGROSUPER, UNITED UTILITIES, THAMES WATER SEVERN TRENT,YORKSHIRE WATER, VALERO, SMURFITT KAPPA etc...
The know-how of our skilled workers, some of whom have more than 30 years of experience, is perpetuated through recruitment programs and training of apprentices in the FABRICATION, MACHINING, WELDING, FITTING AND INSTALLLING PLUS COMMISSIONING.
Our brands: Aerospeed®, Aerostream®, Aircomb®, Aquafenr, Aquadecant®, Aquaeromix®, Aquadisc®, Aquafloat®, Aquatube®, Aquaturbo®, Euromix®, Europelec®, Noemi®, Screwpeller®, Sofie® and TLF®.
Learn more: www.sfa-enviro.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220513005310/en/
Contact information
Contact: Louis-Serge Réal del Sarte, MarCom Director louis-serge@sfa-enviro.com
+33(0)7-62-38-68-82
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom